MarketPulse

Bristol Myers Squibb

2 articles
The Motley FoolThe Motley Fool··Eric Volkman

Bristol Myers Squibb Surges on Strong Q1 Earnings Beat, Growth Portfolio Delivers

Bristol Myers Squibb surges 5% after beating Q1 earnings expectations, with growth portfolio sales up 12% and full-year guidance reaffirmed.
BMYCELGrprofitabilityrevenue beat
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Bristol Myers Squibb and Medtronic Stand Out as Defensive Healthcare Dividend Plays

BMY and MDT offer attractive dividend yields and growth potential, with BMY at 4% yield and MDT boasting 48 years of consecutive increases.
BMYCELGrMDTpharmaceuticalsdividend growth